2,704 Shares in Boston Scientific Co. (NYSE:BSX) Bought by Raleigh Capital Management Inc.

Raleigh Capital Management Inc. bought a new position in shares of Boston Scientific Co. (NYSE:BSX) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 2,704 shares of the medical equipment provider’s stock, valued at approximately $135,000.

Several other large investors have also bought and sold shares of the stock. Koss Olinger Consulting LLC raised its position in Boston Scientific by 3.7% during the 1st quarter. Koss Olinger Consulting LLC now owns 5,322 shares of the medical equipment provider’s stock worth $266,000 after purchasing an additional 191 shares during the last quarter. Clearstead Advisors LLC lifted its holdings in Boston Scientific by 29.6% in the first quarter. Clearstead Advisors LLC now owns 854 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 195 shares during the period. BerganKDV Wealth Management LLC boosted its position in Boston Scientific by 44.3% during the first quarter. BerganKDV Wealth Management LLC now owns 658 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 202 shares during the last quarter. Forum Financial Management LP grew its holdings in Boston Scientific by 1.8% during the 1st quarter. Forum Financial Management LP now owns 11,903 shares of the medical equipment provider’s stock worth $596,000 after acquiring an additional 205 shares during the period. Finally, Dubuque Bank & Trust Co. raised its position in shares of Boston Scientific by 4.3% in the 1st quarter. Dubuque Bank & Trust Co. now owns 5,112 shares of the medical equipment provider’s stock worth $256,000 after acquiring an additional 209 shares in the last quarter. 89.11% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on BSX shares. Piper Sandler raised their target price on Boston Scientific from $58.00 to $62.00 in a research note on Thursday, July 6th. StockNews.com downgraded Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, September 2nd. Mizuho reiterated a “neutral” rating and issued a $56.00 target price on shares of Boston Scientific in a report on Monday, August 28th. Citigroup reaffirmed a “buy” rating and issued a $63.00 price target on shares of Boston Scientific in a research note on Monday, August 28th. Finally, Raymond James lifted their price target on shares of Boston Scientific from $60.00 to $61.00 in a research note on Friday, July 28th. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $58.50.

Insider Activity

In other news, CEO Michael F. Mahoney sold 113,355 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $53.91, for a total transaction of $6,110,968.05. Following the completion of the transaction, the chief executive officer now directly owns 1,498,922 shares of the company’s stock, valued at approximately $80,806,885.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Charles J. Dockendorff sold 17,079 shares of the firm’s stock in a transaction that occurred on Friday, August 18th. The shares were sold at an average price of $50.74, for a total value of $866,588.46. Following the completion of the transaction, the director now directly owns 3,946 shares of the company’s stock, valued at approximately $200,220.04. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Michael F. Mahoney sold 113,355 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $53.91, for a total transaction of $6,110,968.05. Following the completion of the transaction, the chief executive officer now directly owns 1,498,922 shares of the company’s stock, valued at $80,806,885.02. The disclosure for this sale can be found here. Insiders sold 196,794 shares of company stock valued at $10,424,139 in the last three months. Company insiders own 0.71% of the company’s stock.

Boston Scientific Trading Down 0.5 %

Shares of BSX stock opened at $52.92 on Friday. Boston Scientific Co. has a 52-week low of $37.74 and a 52-week high of $54.99. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.80 and a current ratio of 1.29. The company has a 50-day simple moving average of $52.25 and a two-hundred day simple moving average of $51.50. The company has a market capitalization of $77.49 billion, a price-to-earnings ratio of 88.20, a PEG ratio of 2.11 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.53 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.04. The firm had revenue of $3.60 billion during the quarter, compared to the consensus estimate of $3.50 billion. Boston Scientific had a return on equity of 15.16% and a net margin of 6.81%. The business’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.44 EPS. Research analysts anticipate that Boston Scientific Co. will post 1.99 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through MedSurg and Cardiovascular segments. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.